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1056Objective: The vast majority of reports describing beating heart robotic myocardial revascularization (total
endoscopic coronary artery bypass) contain very small numbers of patients undergoing single-vessel bypass.
We present a large series of patients undergoing multivessel total endoscopic coronary artery bypass.
Methods: We performed a retrospective clinical review of 106 patients undergoing total endoscopic coronary
artery bypass (72% multivessel) at 1 institution by 1 experienced cardiac surgeon/physician assistant team.
These results were compared with the expected clinical outcomes from conventional coronary artery bypass
grafting calculated using the Society of Thoracic Surgeons risk calculator.
Results:Of the 106 patients, 1% underwent quadruple total endoscopic coronary artery bypass, 8% triple, 63%
double, and 28% single. The emergent conversion rate for hemodynamic instability was 6.6%. The postoper-
ative renal failure rate (doubling of baseline serum creatinine or dialysis required) was 7.5%. Overall, 23 pa-
tients (21.7%) exhibited at least 1 major morbidity/mortality (4 deaths). The number of vessels bypassed
(single/double/triple/quadruple) correlated positively with the surgical/operating room time, the lung separation
time, vasoactive medication use, blood use, a postoperative ventilation time longer than 24 hours, intensive care
unit length of stay, and hospital length of stay. An increased surgical timewas significantly associated with major
morbidity (P ¼ .011) and mortality (P ¼ .043). A comparison with the Society for Thoracic Surgeons expected
outcomes revealed a similar hospital length of stay but an increased incidence of prolonged ventilation
(P ¼ .003), renal failure (P<.001), morbidity (P ¼ .045), and mortality (P ¼ .049).
Conclusions:Our results suggest that addressing multivessel coronary artery disease using total endoscopic cor-
onary artery bypass offers no obvious clinical benefits and might increase the morbidity and mortality. (J Thorac
Cardiovasc Surg 2012;143:1056-61)Minimally invasive surgery has potential benefits (facili-
tated rehabilitation/discharge) but also has potential risks
(increased complexity).1 Total endoscopic coronary artery
bypass (TECAB) is performed using a robotic system that
allows the surgeon to operate through a series of small tho-
racic incisions. Such surgery was first performed in humans
in 1998,2 ushering in a new era in cardiothoracic surgery.3,4
Most reports using robotic technology during cardiac sur-
gery have done so with some form of minithoracotomy and/
or cardiopulmonary bypass (CPB), with or without myocar-
dial arrest.5-10 The few reports describing TECAB (without
minithoracotomy/CPB) have contained small numbers of
patients undergoing single-vessel coronary artery bypasse Department of Anesthesia and Critical Care,a University of Chicago
er School of Medicine, Chicago, Ill; Department of Health Studies,b Statis-
nalysis, University of Chicago, Chicago, Ill; and Department of Surgery,c
rsity of Chicago Pritzker School of Medicine, Chicago, Ill.
res: Authors have nothing to disclose with regard to commercial support.
d for publication May 19, 2011; revisions received June 2, 2011; accepted for
ation June 27, 2011; available ahead of print Dec 15, 2011.
for reprints: Mark A. Chaney, MD, Department of Anesthesia and Critical
University of Chicago Medical Center, 5841 South Maryland Avenue, MC
Chicago, IL 60637 (E-mail: mchaney@dacc.uhcicago.edu).
23/$36.00
ht 2012 Published by Elsevier Inc. on behalf of The American Association
acic Surgery
016/j.jtcvs.2011.06.023
The Journal of Thoracic and Cardiovascular Surgrafting (CABG).11-16 We report our experience with
multivessel TECAB and compared the outcomes with the
expected outcomes from conventional CABG calculated
using the Society of Thoracic Surgeons (STS) risk
calculator. The use of robotic assistance in cardiac
surgery remains controversial.17-20 Our analysis has
helped to clarify the potential benefits and risks associated
with this technology.METHODS
The University of Chicago institutional review board approved the pres-
ent study and informed consent was waived. We retrospectively reviewed
the records of all 106 patients who had undergone TECAB from July
2007 to February 2009 at our institution. One cardiac surgeon/physician as-
sistant (CS/PA) team performed every TECAB, with 1 of 6 experienced
cardiac anesthesiologists. All were scheduled for off-pump beating heart
1- to 4-vessel TECAB using the da Vinci robotic system (Intuitive Surgical,
Sunnyvale, Calif). Clinically important right coronary artery disease
thought amenable to percutaneous coronary intervention was scheduled
for stent placement after TECAB (before hospital discharge).
After application of standard monitors, anesthesia was induced with in-
travenous midazolam, fentanyl, propofol, and vecuronium, and the patient
was intubated with a left-sided double-lumen endotracheal tube. A radial
arterial line and a right internal jugular vein introducer were inserted.
A pulmonary artery catheter and transesophageal echocardiographic probe
were used in all patients. External defibrillation patches were appropriately
placed. Surgery was performed with single-lung ventilation (whengery c May 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
CS/PA ¼ cardiac surgeon/physician
assistant
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
HLOS ¼ hospital length of stay
ICU ¼ intensive care unit
LAD ¼ left anterior descending
LIMA ¼ left internal mammary artery
pRBCs ¼ packed red blood cells
RIMA ¼ right internal mammary artery
STS ¼ Society of Thoracic Surgeons
TECAB ¼ total endoscopic coronary artery
bypass
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Drequested by the surgeon for exposure), and the patient was positioned su-
pine. Intravenous nitroglycerin (5 mg/min) and lidocaine (l mg/min) were
administered to attenuate coronary artery spasm and prevent reperfusion
arrhythmias.
Surgery was performed as previously described by Srivastava and col-
leagues.17 After single-lung ventilation was achieved, intercostal incisions
were made (variations determined from revascularization schemes). Car-
bon dioxide was used to insufflate the chest (usually 10–15 mm Hg), and
the robotic arms were placed. With the CS at the console and the PA
scrubbed and in the field controlling the robotic instrumentation, the left in-
ternal mammary artery (LIMA) and, if needed, the right internal mammary
artery (RIMA) were harvested. Pericardiotomy was performed, the target
sites were identified, and a cannula was inserted through a subcostal
port. Systemic intravenous heparinization (100 U/kg) was achieved (target
activated clotting time, 250 seconds). A myocardial stabilizer was used to
minimize movement of the target vessels. When all anastomotic sites ap-
peared satisfactory, intravenous protamine (10 mg/kg) was administered.
A Doppler probe was used to assess the flow measurements. A chest
tube drain was inserted behind the left lung, followed by gentle reinflation
of the left lung. The thoracic incisions were then surgically closed.
The patients were transported to the intensive care unit (ICU), usually
with a single-lumen endotracheal tube or spontaneously ventilating after
extubation in the operating room (OR). The goal was extubation 2 to 4
hours after ICU arrival. Mobilization by physical therapists occurred on
the second postoperative day (POD), and the lines were removed. The pa-
tients were transferred to the rehabilitation floor when clinically
appropriate.
The preoperative records (anesthesia, surgery) were reviewed for demo-
graphic data, comorbid conditions, number of diseased vessels, and sever-
ity of ventricular dysfunction. The OR records (surgery, nursing, perfusion)
revealed the number of grafts performed, surgical time, and OR time. The
anesthesia records provided the total lung separation time, use/nonuse of
vasopressors (continuous infusion of dobutamine, epinephrine, neosy-
nephrine, norepinephrine, and/or vasopressin), urine output, and any clin-
ical problems. The postoperative records (ICU, floor notes) were reviewed
for the interval to extubation, ICU length of stay (ILOS), hospital length of
stay (HLOS), morbidity, and mortality.
The logistic version of the European System for Cardiac Operative Risk
Evaluation (euroSCORE) was used to calculate the predicted perioperative
mortality for each patient.21 Postoperative renal failure was defined as the
doubling of the preoperative serum creatinine or new requirement forThe Journal of Thoracic and Carpostoperative dialysis. Bleeding was considered ‘‘excessive’’ if transfusion
of 6 or more units of packed red blood cells (pRBCs) occurred within 24
hours after the surgical incision. Major morbidity was defined as ventricu-
lar trauma, emergent conversion, excessive bleeding, renal failure, acute
graft failure, incomplete revascularization (inability to perform surgical by-
pass, inability to insert a coronary stent, or unaddressed disease found by
postoperative angiography), or gross stroke.
The demographic, disease, and surgical characteristics and outcomes
are summarized using the mean, standard deviation, and range or frequency
counts and percentages. Comparisons across the groups were made using
the Wilcoxon rank-sum test for continuous variables or chi-square tests
(or Fisher’s exact tests, as appropriate) for categorical variables. When
comparing the 2 series of patients, 2-sample t tests were used for continu-
ous variables because the raw data from Srivastava and colleagues17 were
unavailable. The correlations between the continuous or ordinal (eg, num-
ber of vessels bypassed) were assessed using Spearman rank correlation co-
efficients. The Cochran-Armitage trend test was used to examine whether
the proportion of patients with morbidity, mortality, pRBC use, vasoactive
medication use, or prolonged ventilation increased with an increasing num-
ber of vessels bypassed. Logistic regression models were fit to assess the
likelihood of certain outcomes (eg, pRBCs or vasoactive medication use)
stratified by the surgical time. In addition, 1 degree of freedom goodness
of fit chi-square tests were performed to compare the number of patients
with a particular outcome in the present series with that expected according
to the STS risk calculator. A 2-sided P<.05 was considered statistically
significant. No adjustments for multiple comparisons were made. All
analyses were performed using Stata, version 11 (StataCorp, College
Station, Tex).RESULTS
From July 2007 to February 2009, 106 patients under-
went TECAB. The preoperative demographic and intrao-
perative data are listed in Table 1.
A total of 39 patients (36.8%) experienced morbidity or
mortality (Table 2). Some patients were counted more than
once in Table 2 (eg, emergent conversion with postoperative
pneumothorax). One intraoperative RIMA-obtuse marginal
tear resulted in cardiac arrest and emergent thoracotomy
(with CPB) for revision. The patient then returned to the
OR the next day for additional revision (median sternot-
omy). A patient with right ventricular trauma returned to
the OR for repair of bleeding from the LIMA-left anterior
descending (LAD) anastomosis and right ventricular tear
site. Left ventricular trauma in 1 patient was caused by
the myocardial stabilizer and required emergent sternot-
omy. Four patients underwent elective intraoperative con-
version by way of a thoracotomy (not considered
a morbidity). All required elective conversion because of
surgical technical difficulty. Seven patients underwent
emergent perioperative conversion because of hemody-
namic instability. Five required sternotomy (2 intraopera-
tive, 3 requiring a return to the OR) and 2 required
thoracotomy (both intraoperative). Of the 3 intraoperative
CPB initiations, 2 were emergent. The 1 elective CPB initi-
ation (closed chest) was required for hemodynamic instabil-
ity (the patient also experienced postoperative stroke).
Eight patients developed postoperative renal failure, of
whom, 3 required dialysis. Seven patients had incompletediovascular Surgery c Volume 143, Number 5 1057
TABLE 1. Preoperative demographics/intraoperative data (n ¼ 106)
Variable Value
Age (y)
Mean  SD 63.6  11.5
Range 38–87
Female gender (n) 27 (25.5)
Body mass index (kg/m2)
Mean  SD 30.4  6.2
Range 17.6–58.0
Hypercholesterolemia (n) 78 (73.6)
Hypertension (n) 98 (92.5)
Diabetes mellitus (n) 36 (34.0)
History of smoking (n) 29 (27.4)
Peripheral vascular disease (n) 5 (4.7)
Cerebral vascular disease (n) 10 (9.4)
Preoperative creatinine>2.0 mg/dL (n) 2 (2.2)
Ejection fraction<50% (n) 24 (23.8)
Previous myocardial infarction (n) 30 (28.3)
Triple-vessel coronary artery disease (n) 76 (71.7)
Left ventricular ejection fraction (%)
Mean  SD 53.9  13.0
Range 16–76
Repeat coronary artery bypass grafting (n) 2 (1.9)
euroSCORE
Mean  SD 3.2  3.5
Range 0.9–24.4
‘‘Low-risk’’ euroSCORE (<3) (n) 69 (65.1)
‘‘Moderate-risk’’ euroSCORE (3–5) (n) 24 (22.6)
‘‘High-risk’’ euroSCORE (6) (n) 13 (12.3)
Four-vessel TECAB (n) 1 (0.9)
Three-vessel TECAB (n) 8 (7.5)
Two-vessel TECAB (n) 67 (63.2)
One-vessel TECAB (n) 30 (28.3)
LIMA/RIMA (n) 55 (51.9)
Total surgical time (min)
Mean  SD 326  139
Range 125–876
Total lung separation time (min)
Mean  SD 269  123
Range 0–660
Total operating room time (min)
Mean  SD 451  142
Range 240–1007
Total urine output (mL/kg/hr)
Mean  SD 0.7  0.4
Range 0.1–2.0
Vasopressor infusion required (n) 55 (51.9)
Data in parentheses are percentages. euroScores calculated as described by Nashef
et al.21 SD, Standard deviation; euroSCORE, European System for Cardiac Operative
Risk Evaluation; TECAB, total endoscopic coronary artery bypass; LIMA/RIMA, left
internal mammary artery/right internal mammary artery (dissection).
TABLE 2. Morbidity/mortality
Period Patients (n)
Intraoperative
RIMA trauma 1
Ventricular trauma 2
Cardiac arrest 1
Emergent conversion 4
CPB initiation 3
Death 1
Postoperative
New-onset atrial fibrillation 17
Pneumothorax 2
Renal failure 8
New-onset dialysis 3
Incomplete revascularization 7
Acute graft failure 3
IABP insertion 3
Cardiac arrest 1
Reintubation 2
Stroke 2
Excessive bleeding 7
Return to operating room 4
Death 3
RIMA, Right internal mammary artery; CPB, cardiopulmonary bypass; IABP, intra-
aortic balloon pump.
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Drevascularization, and 3 experienced graft failure during the
postoperative period (one 80% RIMA graft stenosis as-
sessed through angiography; 2 required LIMA-LAD stent).
Four returned to the OR for excessive bleeding (3 sternoto-
mies and 1 thoracotomy).1058 The Journal of Thoracic and Cardiovascular SurSeven patients were extubated in the OR. Of the remain-
ing 99, 86 were extubated within 24 hours of ICU arrival,
and 13 were extubated more than 24 hours after ICU arrival.
The mean ILOS was 2.3 days (range, 0–22), and the mean
HLOS was 5.2 days (range, 2–24).
Of the 106 patients, 23 (21.7%) exhibited major morbid-
ity. The surgical time for the patients with major morbidity
was significantly longer than that for the patients without
major morbidity (414 191 minutes vs 302 111 minutes,
respectively, P ¼ .011). The decrease in the major morbid-
ity/mortality rates over time (ie, with more experience) was
not statistically significant. The rate was 35% among the
first 26 patients, 19% among the next 27 patients, 22%
among the next 27 patients, and 12% among the last 26 pa-
tients (Cochran-Armitage trend test, P ¼ .071).
Four patients died. The first was a 69-year-old woman
(ejection fraction, 51%; euroSCORE, 3.79) scheduled for
2-vessel TECAB. Elective conversion (thoracotomy) was
required. A LIMA-LAD graft was performed; however,
the right coronary artery was not revascularized. Postoper-
ative infarction (right coronary artery territory) required
intra-aortic balloon pump insertion, and renal failure (dial-
ysis) preceded death on POD 4. The second was a 58-year-
old woman (ejection fraction, 40%; euroSCORE, 1.85)
scheduled for 2-vessel TECAB. LIMA-obtuse marginal
and RIMA-LAD grafts were performed. Ventricular fibrilla-
tion immediately after surgery led to emergent sternotomy/
initiation of CPB. Additional revascularization was per-
formed; however, this patient was unable to be weanedgery c May 2012
TABLE 3. Comparison of revascularization groups (n ¼ 106)
Variable One-vessel TECAB Two-vessel TECAB Three/four-vessel TECAB P value
Total patients (n) 30 (28) 67 (63) 9 (9)
euroSCORE 3.3  2.6 3.3  3.9 1.7  1.4 .144
Lung separation time (min) 174  73* 283  99 464  136 <.001
Surgical time (min) 220  102* 342  100 564  150 <.001
Operating room time (min) 346  107* 466  101 695  160 <.001
Vasoactive medications (n) 11 (36.7)* 37 (55.2) 7 (77.8) .019
pRBC use (n) 1 (3.3) 3 (4.5) 3 (33.3) .021
Renal failure (n) 3 (10.0) 5 (7.5) 0 (0.0) .364
Postoperative ventilation>24 h (n) 1 (3.3) 9 (13.4) 3 (33.3) .018
ILOS (d) 1.7  1.3 2.4  3.0 3.6  1.5 .002
HLOS (d) 4.2  1.7* 5.3  3.4 7.2  3.3 .004
Major morbidity (n) 7 (23.3) 12 (17.9) 4 (44.4) .522
Mortality (n) 1 (3.3) 2 (3.0) 1 (11.1) .481
Data presented as numbers of patients, with percentages in parentheses, or mean  SD. P values from Spearman rank correlation analysis for continuous variables and Cochran-
Armitage trend tests for dichotomous variables. TECAB, Total endoscopic coronary artery bypass; SD, standard deviation; pRBC, packed red blood cells; ILOS, intensive care unit
length of stay; HLOS, hospital length of stay. *P<.05 compared with patients undergoing multivessel TECAB using Wilcoxon rank-sum tests for continuous variables and chi-
square tests (or Fisher’s exact test, as appropriate) for dichotomous variables.
TABLE 4. Observed versus expected outcomes
Outcome Observed (n) Expected (n)* P valuey
Prolonged ventilation 13 5.94 .003
Short length of stay 71 63.36 .130
Long length of stay 2 3.57 .398
Renal failure 8 2.55 <.001
Stroke 2 0.85 .209
Reoperation 4 3.85 .939
Morbidity 16 9.96 .045
Mortality 4 1.56 .049
*Expected outcomes calculated from Society of Thoracic Surgeons risk calculator
(available from: www.sts.org), which allows a user to calculate a patient’s risk of mor-
bidity and mortality. The risk calculator incorporates the Society of Thoracic Sur-
geons risk models, which are designed to serve as statistical tools to account for
the effect of patient risk factors on operative morbidity and mortality. STS outcomes
definitions include prolonged ventilation (tracheal extubation >24 hours), short
length of stay (hospital discharge<6 days), long length of stay (hospital discharge
>14 days), renal failure (serum creatinine increase to>2.0 mg/dL, doubling of pre-
operative creatinine, or new requirement for dialysis); stroke (confirmed neurologic
deficit of abrupt onset that does not resolve within 24 hours); reoperation (for bleed-
ing/tamponade, valvular dysfunction, graft occlusion, other cardiac or noncardiac
reasons); morbidity (composite endpoint of operative mortality, permanent stroke, re-
nal failure, prolonged ventilation>24 hours, deep sternal wound infection, and reop-
eration); mortality (death during hospitalization, even if after 30 days or deaths after
hospital discharge but within 30 days of procedure unless the cause of death was
clearly unrelated to the operation). yFrom 1 degree of freedom chi-square goodness
of fit test.
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patient was an 85-year-old man (ejection fraction, 62%;
euroSCORE, 4.79) scheduled for 2-vessel TECAB. Elec-
tive conversion (thoracotomy) allowed surgery to be per-
formed uneventfully (LIMA-LAD, vein graft-diagonal).
However, postoperative myocardial failure (postoperative
ejection fraction 10%), and renal failure (dialysis) preceded
death on POD 6. The fourth was a 71 year-old female
(ejection fraction, 55%; euroSCORE, 2.68) scheduled for
4-vessel TECAB, which was performed uneventfully
(LIMA-obtuse marginal/ramus, RIMA-LAD, vein graft-
diagonal). However, the patient returned to the OR because
of excessive bleeding (emergent sternotomy) after cardiac
arrest in the ICU. Subsequent stroke preceded death on
POD 8. The surgical time in patients with mortality was
significantly longer than in patients without mortality
(506  190 minutes vs 319  132 minutes, respectively,
P ¼ .043).
The comparison of the revascularization groups is given
in Table 3. An increasing number of vessels bypassed was
significantly associated with increased vasoactive medica-
tion use (P ¼ .019), pRBC use (P ¼ .021), the occurrence
of postoperative ventilation times longer than 24 hours
(P¼ .018), and ILOS (P¼ .002). The number of vessels by-
passed also correlated positively with lung separation time
(r ¼ 0.615; P<.001), surgical time (r ¼ 0.686; P<.001),
OR time (r ¼ 0.669; P< .001), and HLOS (r ¼ 0.279;
P¼ .004). Compared with patients undergoing 1-vessel TE-
CAB, patients undergoing multivessel TECAB had signifi-
cantly prolonged surgical and OR times (P<.001 for both)
and HLOS (P ¼ .027). An increased surgical time was sig-
nificantly associated with increased lung separation time
(r ¼ 0.782; P<.001), HLOS (r ¼ 0.332; P<.001), an in-
creased likelihood of vasoactive medication use (odds ratio,
1.80 per standard deviation increase in surgical time; 95%The Journal of Thoracic and Carconfidence interval, 1.14–2.84; P ¼ .011), pRBC use (odds
ratio, 2.68 per standard deviation increase in surgical time;
95% confidence interval, 1.34–5.35; P ¼ .005), and pro-
longed postoperative ventilation time (odds ratio, 1.80 per
standard deviation increase in surgical time; 95% confi-
dence interval, 1.07–3.04; P ¼ .028).
The observed outcomes in our patients compared with the
expected outcomes from conventional CABG using the STS
risk calculator (available from www.sts.org) are listed in
Table 4. Our patients had a significantly greater incidencediovascular Surgery c Volume 143, Number 5 1059
TABLE 5. Comparison of studies by Srivastava et al17 and present
study
Variable Srivastava et al17 Present study
Total patients reported (n) 93 106
Study period Jul 2004–Dec 2005 Jul 2007–Feb 2009
Mean age (y) 67.4  12.3 63.6  11.5*
Number of vesselsy
One-vessel TECAB (n) 54 (58) 30 (28)
Two-vessel TECAB (n) 35 (38) 67 (63)
Three-vessel TECAB (n) 4 (4) 8 (8)
Four-vessel TECAB (n) 0 (0) 1 (1)
Multivessel TECAB (n) 39 (42) 76 (72)y
LIMA/RIMA (n) 38 (41) 55 (52)
Perioperative sternotomy (n) 0 (0) 5 (5)
Emergent conversion (n) 0 (0) 7 (7)*
CPB required (n) 0 (0) 3 (3)
Mean operating room time
(min)
272  128 451  142y
Stroke (n) 0 (0) 2 (2)
Return to operating room (n) 0 (0) 4 (4)
In-hospital mortality (n) 0 (0) 4 (4)
Mean hospital length of stay (d) 3.4  2.0 5.2  3.1y
Data presented as mean  standard deviation; data in parentheses are percentages.
TECAB, Total endoscopic coronary artery bypass; LIMA/RIMA, left internal mam-
mary artery/right internal mammary artery dissection;CPB, cardiopulmonary bypass.
*P<.05. yP<.001.
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Dof prolonged ventilation, renal failure, morbidity, and
mortality.
DISCUSSION
TECAB for multivessel disease has been described as
‘‘uncharted territory.’’18 Our series represents the largest re-
ported pool of patients undergoing multivessel TECAB.We
found that increasing the number of vessels bypassed signif-
icantly increased the surgical/OR time, lung separation
time, vasoactive medication use, pRBC use, postoperative
ventilation time, ILOS, and HLOS. Furthermore, the in-
creased surgical time was significantly associated with ma-
jor morbidity and mortality. Finally, a comparison with the
STS expected outcomes revealed a similar HLOS but a sig-
nificantly increased incidence of prolonged ventilation, re-
nal failure, morbidity, and mortality. Our results suggest
that addressing multivessel disease by way of TECAB of-
fers no obvious clinical benefits and might increase the mor-
bidity and mortality.
The vast majority of reports using robotic technology
during cardiac surgery have done sowith some form of min-
ithoracotomy and/or CPB (with/without myocardial arrest)
and usually describe single-vessel revascularization
(LIMA-LAD).5-10 All have reported prolonged surgical/
OR times—perhaps the ‘‘payoff necessary to avoid
sternotomy or thoracotomy.’’8 However, elective
conversion rates (to sternotomy/full thoracotomy) hover
around 20%.5,6,8 Potential benefits include enhanced
postoperative recovery7 and decreased postoperative atrial
fibrillation.9 Perioperative blood use might be decreased9
or increased.5 Unresolved issues include increased costs7
and increased technical difficulty.5,6 All have described
a substantial learning curve.6,10
The few reports describing TECAB (without minithora-
cotomy/CPB) involve small numbers of patients undergo-
ing single-vessel revascularization.11-16 We also found
many of the same concerns listed previously. Falk and
colleagues16 described 12 patients (all with single
LIMA-LAD) and the ‘‘substantial learning curve.’’ Katz
and colleagues15 and Gao and colleagues12 reported on
27 patients and 4 patients (all with single LIMA-LAD), re-
spectively, undergoing combined TECAB and percutane-
ous coronary intervention for multivessel disease. Gao
and colleagues12 reported that TECAB ‘‘is very demand-
ing.’’ All reported long operation times and a substantial
learning curve and believed this technology should be re-
served for single-vessel revascularization in healthy pa-
tients.11 de Canniere and colleagues,14 in a multicenter
report (5 centers, 74 patients, 90% single-vessel disease),
found that target vessel reintervention was greater than
that reported for conventional CABG and stated that TE-
CAB had ‘‘difficulties that must not be underestimated.’’
Others have questioned the issue of graft patency. Bonatti
and colleagues20 detailed 40 patients undergoing single-1060 The Journal of Thoracic and Cardiovascular Survessel (LIMA-LAD) robotic revascularization (CPB, ar-
rested heart), of whom 50% experienced ‘‘undesirable
technical events’’ and 20% experienced ‘‘anastomotic
problems.’’ Kappert and colleagues13 described 5-year
follow-up data for 33 patients who underwent TECAB
(95%, single; 5%, double) and found an unacceptably
high (13%) LAD reintervention rate. They concluded
that ‘‘clinical outcomes and need for reintervention of
the target vessel leave room for improvement.’’13
Two editorials have summed up the controversy sur-
rounding TECAB.3,4 One is fairly optimistic: ‘‘The reality
is, at present, no one can predict whether robotic
technology is or is not going to play a major role in the
future of cardiac surgery.’’4 The other is not: ‘‘It is time to
recognize that robotics are no longer a promising new tech-
nology but instead a technology that has been tried and has
failed to demonstrate any clinical value, outside of its ques-
tionable use for marketing.’’3
A comparison of our results with those of Srivastava and
colleagues17 provides additional unique insight. These 2 se-
ries (Table 5) represent the largest reported number of pa-
tients undergoing multivessel TECAB and the same
experienced CS/PA team performed all the surgeries (at 2
different institutions). This previous experience likely led
to our inability to find strong evidence of a learning curve.
Our patient population was quite different from that of Sri-
vastava and colleagues17 (72% multivessel vs 42% multi-
vessel TECAB, P < .001). Furthermore, Srivastava and
colleagues17 reported a 13.8% exclusion/conversion rategery c May 2012
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sion or a need for sternotomy and/or CPB, and 18 patients
(19.4%) underwent planned hybrid revascularization (no
failures reported).17 A comparison of these 2 series supports
the notion that addressing multivessel coronary artery dis-
ease using TECAB might increase the morbidity and mor-
tality. However, for a wide variety of reasons (different
periods, different institutions, different perioperative per-
sonnel, and so forth), a comparison of these 2 studies might
be inappropriate.
Intraoperative hemodynamic instability is a challenging
clinical reality of TECAB.11,14,17,18,22 Carbon dioxide
insufflation (essentially a pneumothorax) leads to cardiac
displacement and decreased venous return, when coupled
with potential hypoxemia/hypercarbia (prolonged single-
lung ventilation), might lead to increased central venous
pressure, increased pulmonary artery pressure, decreased
cardiac output, and hypotension.11,14,17 Right ventricular
dysfunction (single-lung ventilation-initiated atelectasis,
hypoxic vasoconstriction) and/or left ventricular dysfunc-
tion (compliance changes) might also contribute.18 Such he-
modynamic instability necessitates preload augmentation
and/or the use of inotropes/vasoconstrictors. We hypothe-
sized that increasing the number of vessels bypassed (thus
increasing the single-lung ventilation time/surgical time)
promotes greater hemodynamic instability (increasing va-
soactive medication use) and might be the underlying etiol-
ogy of the increased morbidity and mortality observed.
Because of this procedure-induced hemodynamic instabil-
ity, many have recommended TECAB only for single-
vessel disease in patients with reasonable cardiopulmonary
reserve.11,14,18
Our study had all the inherent limitations associated with
a retrospective analysis. Furthermore, one must remember
that the predicted outcomes using the STS risk calculator
are only an estimate. However, we specifically defined all
major morbidities assessed. Additionally, the morbidities
we believed were more along the lines of ‘‘clinical chal-
lenges’’ (elective conversion, new-onset atrial fibrillation)
were not considered major morbidities. Also, to best com-
pare the outcomes from TECAB versus conventional
CABG, a randomized controlled trial would be ideal.
In conclusion, we have reported the largest series to date
of patients undergoing multivessel TECAB by 1 CS/PA
team at a single institution and compared the findings
with expected outcomes from conventional CABG and
with the same CS/PA team’s experience at another institu-
tion. Our analysis supported the concerns voiced by others,
that addressing multivessel coronary artery disease with
TECAB offers no obvious clinical benefits and might in-
crease the morbidity and mortality. At present, until efficacy
is proven through proper clinical trials, TECABmyocardial
revascularization should be reserved for relatively healthyThe Journal of Thoracic and Carpatients (reasonable cardiopulmonary reserve) undergoing
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